跳至主要内容
临床试验/NL-OMON46049
NL-OMON46049已完成4 期

A non-interventional biomarker study in patients with NSCLC of adenocarcinoma tumour histology eligible for treatment with Vargatef according to the approved label - Biomarker study in patients with NSCLC

Boehringer Ingelheim0 个研究点目标入组 34 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
34

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Women and men with locally advanced, metastatic or locally recurrent NSCLC with histology of adenocarcinoma
  • - Vargatef is initiated and administered in accordance with the SPC
  • - Available fixed and paraffin embedded (FPE) tumour tissue routinely obtained at diagnosis and/or re-biopsy before the initiation of the first line treatment (either block or slides, minimum of 10 slides and up to 20 slides if possible at 5 um thickness).

排除标准

  • - Any contraindication to Vargatef or docetaxel as specified in their respective labels
  • - Vargatef initiated from more than 7 days prior to inclusion in this NIS
  • - Patients participating simultaneously in another NIS or a clinical trial

研究者

相似试验